Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRui LiuFYFan YangLMLixia Ma

Discussion

Loading...

Member takes

Overview

Prospective phase I/II trial finds CD19 CAR-T improves progression-free survival and manages adverse events in CNS lymphoma patients.

Key Points

  • CD19 CAR-T therapy resulted in a promising outcome for central nervous system lymphoma patients.
  • The overall response rate was 75.6%, with a complete response rate of 66.7%.
  • Phase I/II trial assessed the treatment-related toxicity and established the recommended dose for future studies.
  • Findings highlight the therapeutic potential of CAR-T therapy for hematological malignancies, especially in CNS involvement.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8cdhttps://doi.org/10.1182/blood-2025-672
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK2025
  2. 2Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma2025
  3. 3CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry2025
  4. 4Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025
  5. 5Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma2025